243 related articles for article (PubMed ID: 16930951)
1. Pharmacodynamic profiling of imipenem, meropenem and ertapenem against clinical isolates of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella spp. from Brazil.
Kiffer CR; Kuti JL; Eagye KJ; Mendes C; Nicolau DP
Int J Antimicrob Agents; 2006 Oct; 28(4):340-4. PubMed ID: 16930951
[TBL] [Abstract][Full Text] [Related]
2. Pharmacodynamic modeling of carbapenems and fluoroquinolones against bacteria that produce extended-spectrum beta-lactamases.
Moczygemba LR; Frei CR; Burgess DS
Clin Ther; 2004 Nov; 26(11):1800-7. PubMed ID: 15639692
[TBL] [Abstract][Full Text] [Related]
3. Bactericidal activities of meropenem and ertapenem against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a neutropenic mouse thigh model.
DeRyke CA; Banevicius MA; Fan HW; Nicolau DP
Antimicrob Agents Chemother; 2007 Apr; 51(4):1481-6. PubMed ID: 17283197
[TBL] [Abstract][Full Text] [Related]
4. Comparative in vitro activity of ertapenem against extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae isolated in Spain.
Hernández JR; Velasco C; Romero L; Martínez-Martínez L; Pascual A
Int J Antimicrob Agents; 2006 Nov; 28(5):457-9. PubMed ID: 17008066
[TBL] [Abstract][Full Text] [Related]
5. [Investigation of the susceptibilities of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella spp. strains to ertapenem and other carbapenems].
Kuzucu C; Yetkin F; Görgeç S; Ersoy Y
Mikrobiyol Bul; 2011 Jan; 45(1):28-35. PubMed ID: 21341156
[TBL] [Abstract][Full Text] [Related]
6. First national surveillance of susceptibility of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella spp. to antimicrobials in Israel.
Colodner R; Samra Z; Keller N; Sprecher H; Block C; Peled N; Lazarovitch T; Bardenstein R; Schwartz-Harari O; Carmeli Y;
Diagn Microbiol Infect Dis; 2007 Feb; 57(2):201-5. PubMed ID: 17258084
[TBL] [Abstract][Full Text] [Related]
7. Ertapenem susceptibility of extended spectrum beta-lactamase-producing Enterobacteriaceae at a tertiary care centre in India.
Behera B; Mathur P; Das A; Kapil A
Singapore Med J; 2009 Jun; 50(6):628-32. PubMed ID: 19551319
[TBL] [Abstract][Full Text] [Related]
8. In vitro killing of parenteral beta-lactams against standard and high inocula of extended-spectrum beta-lactamase and non-ESBL producing Klebsiella pneumoniae.
Burgess DS; Hall RG
Diagn Microbiol Infect Dis; 2004 May; 49(1):41-6. PubMed ID: 15135499
[TBL] [Abstract][Full Text] [Related]
9. In vitro activity of cefepime, imipenem, tigecycline, and gentamicin, alone and in combination, against extended-spectrum beta-lactamase-producing Klebsiella pneumoniae and Escherichia coli.
Cha R
Pharmacotherapy; 2008 Mar; 28(3):295-300. PubMed ID: 18294108
[TBL] [Abstract][Full Text] [Related]
10. Pharmacodynamic activity of ertapenem versus multidrug-resistant genotypically characterized extended-spectrum beta-lactamase-producing Escherichia coli using an in vitro model.
Zhanel GG; Baudry P; Vashisht V; Laing N; Noreddin AM; Hoban DJ
J Antimicrob Chemother; 2008 Mar; 61(3):643-6. PubMed ID: 18238885
[TBL] [Abstract][Full Text] [Related]
11. Ertapenem susceptibility of extended spectrum beta-lactamase-producing organisms.
Mody RM; Erwin DP; Summers AM; Carrero HA; Selby EB; Ewell AJ; Moran KA
Ann Clin Microbiol Antimicrob; 2007 Jun; 6():6. PubMed ID: 17553151
[TBL] [Abstract][Full Text] [Related]
12. Pharmacodynamic target attainment of six beta-lactams and two fluoroquinolones against Pseudomonas aeruginosa, Acinetobacter baumannii, Escherichia coli, and Klebsiella species collected from United States intensive care units in 2004.
DeRyke CA; Kuti JL; Nicolau DP
Pharmacotherapy; 2007 Mar; 27(3):333-42. PubMed ID: 17316145
[TBL] [Abstract][Full Text] [Related]
13. In vitro activities of three carbapenems against recent bacterial isolates from severely ill patients at Swedish hospitals.
Fraenkel CJ; Ullberg M; Bernander S; Ericson E; Larsson P; Rydberg J; Törnqvist E; Melhus A
Scand J Infect Dis; 2006; 38(10):853-9. PubMed ID: 17008228
[TBL] [Abstract][Full Text] [Related]
14. Effects of phenotype and genotype on methods for detection of extended-spectrum-beta-lactamase-producing clinical isolates of Escherichia coli and Klebsiella pneumoniae in Norway.
Tofteland S; Haldorsen B; Dahl KH; Simonsen GS; Steinbakk M; Walsh TR; Sundsfjord A;
J Clin Microbiol; 2007 Jan; 45(1):199-205. PubMed ID: 17079502
[TBL] [Abstract][Full Text] [Related]
15. Pharmacodynamic profiling of intravenous antibiotics against prevalent Gram-negative organisms across the globe: the PASSPORT Program-Asia-Pacific Region.
Roberts JA; Kwa A; Montakantikul P; Gomersall C; Kuti JL; Nicolau DP
Int J Antimicrob Agents; 2011 Mar; 37(3):225-9. PubMed ID: 21168997
[TBL] [Abstract][Full Text] [Related]
16. In vitro susceptibility pattern of cephalosporin-resistant Gram-negative bacteria.
Punpanich W; Tantichattanon W; Wongwatcharapaiboon S; Treeratweeraphong V
J Med Assoc Thai; 2008 Oct; 91 Suppl 3():S21-7. PubMed ID: 19255989
[TBL] [Abstract][Full Text] [Related]
17. Pharmacodynamic modeling of intravenous antibiotics against gram-negative bacteria collected in the United States.
Koomanachai P; Bulik CC; Kuti JL; Nicolau DP
Clin Ther; 2010 Apr; 32(4):766-79. PubMed ID: 20435246
[TBL] [Abstract][Full Text] [Related]
18. Comparison of disk diffusion, Etest and VITEK2 for detection of carbapenemase-producing Klebsiella pneumoniae with the EUCAST and CLSI breakpoint systems.
Vading M; Samuelsen Ø; Haldorsen B; Sundsfjord AS; Giske CG
Clin Microbiol Infect; 2011 May; 17(5):668-74. PubMed ID: 20649801
[TBL] [Abstract][Full Text] [Related]
19. [Antibiotic resistance rates of extended spectrum beta-lactamase producing Escherichia coli and Klebsiella spp. strains isolated from urinary tract infections in a private hospital].
Akyar I
Mikrobiyol Bul; 2008 Oct; 42(4):713-5. PubMed ID: 19149097
[TBL] [Abstract][Full Text] [Related]
20. Determination of the pharmacodynamic activity of clinically achievable tigecycline serum concentrations against clinical isolates of Escherichia coli with extended-spectrum beta-lactamases, AmpC beta-lactamases and reduced susceptibility to carbapenems using an in vitro model.
Zhanel GG; Baudry PJ; Tailor F; Cox L; Hoban DJ; Karlowsky JA
J Antimicrob Chemother; 2009 Oct; 64(4):824-8. PubMed ID: 19643776
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]